Faster and More Efficient Detection of Varicella Zoster Virus (VZV) Infections

Improved VZV Antibody Detection with a New Lateral Flow Assay

Varicella zoster virus (VZV) is a member of the herpesvirus family that can infect humans and cause chickenpox (mostly in children and young adults) and shingles in adults. The ability to accurately detect the presence of VZV specific antibodies is important for identifying individuals who may be at risk for complications or who require vaccination. 

Diagnostic tests allow healthcare professionals to efficiently screen children, adolescents, and adults for their immunity status by detecting the levels of VZV antibodies in a person’s blood circulation.  The current standard to detect previous infection (or vaccination) of VZV is through serologic IgG tests. Currently, enzyme-linked immunosorbent assays (ELISAs) are used to detect VZV antibodies in human serum samples; however, the collection, transport, and processing of blood samples required for ELISAs can be time-consuming and costly.

A collaboration between Viro Research, DCN Dx, and Partners in Diagnostics has led to the development of a lateral flow assay (LFA) that detects VZV antibodies more efficiently using human whole blood via fingerstick collection. The researchers published their findings in the Journal of Immunological Methods and the paper describes the development and testing of the VZV LFA.

What Were the Results?

Compared to conventional ELISA testing, the VZV LFA is a faster and simpler point-of-care test that can be used to detect VZV antibodies in human capillary blood using a fingerstick collection. The analytical performance and clinical study results showed that the VZV LFA is comparable to or better than ELISA testing. Initial findings indicate that the VZV LFA is also robust enough to be used in CLIA-waived point-of-care facilities by untrained healthcare workers.

The new VZV LFA test represents a significant advancement in VZV antibody detection, enabling faster and more efficient detection of previous VZV infections. This development has important implications for healthcare providers, as it provides a more accessible and convenient method for detecting VZV antibodies in patients who may require vaccination or monitoring for complications associated with VZV infections.

About DCN Dx

DCN Dx is a global leader in the design, development, and manufacture of point-of-use diagnostics. Based in Carlsbad, California, our multidisciplinary team of scientists and engineers collaborates to create and integrate comprehensive assay systems, consumables, and instruments tailored for point-of-use applications. These reliable systems empower users to detect and quantify biomarkers and pathogens, thereby facilitating the timely delivery of treatments.

We partner with both biotech start-ups and established industry leaders to develop state-of-the-art rapid diagnostic tests. Our clinical research services and engineering teams ensure that products are designed with a focus on usability, manufacturability, and high-performance capabilities. Our experience encompasses a range of segments and applications, including clinical point-of-care testing, veterinary diagnostics, bioprocessing, soil and water testing, food safety, force protection, and more.

DCN Dx is committed to delivering innovative solutions and exceptional service to meet the diverse needs of our clients. To learn more, visit dcndx.com.